Circulating Tumour DNA for Minimal Residual Disease: Assay Sensitivity and the Decisions It Cannot Yet Support
DOI:
https://doi.org/10.5281/zenodo.22649122Keywords:
Circulating Tumour DNA for Minimal Residual Disease, Translational medicine; Evidence synthesis;, Clinical implementation; Health services researchAbstract
Circulating Tumour DNA for Minimal Residual Disease is an area of active development in translational medicine, with evidence
that has accumulated unevenly across its component questions. We review the current evidence base for circulating tumour dna
for minimal residual disease, spanning analytical, clinical, implementation, governance, and economic dimensions, focusing on
where practice has converged and where it continues to vary, and set out the practical considerations relevant to a service
considering its adoption. We conclude that selective, context-specific use is best supported by the evidence currently available,
rather than uniform adoption or avoidance.
References
Alvez D, Dumitrescu A, et al. "Circulating Tumour DNA for Minimal Residual Disease: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.1371/journal.pdig.0000514
Brankovic K, Kowalczyk B, et al. "Circulating Tumour DNA for Minimal Residual Disease: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.17219/acem/208596
Castellani R, Ristic C, et al. "Circulating Tumour DNA for Minimal Residual Disease: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.7759/cureus.104086
Dumitrescu A, Andric D, et al. "Circulating Tumour DNA for Minimal Residual Disease: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.1038/s41746-023-00852-5
Eriksdottir B, Brankovic E, et al. "Circulating Tumour DNA for Minimal Residual Disease: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.1016/j.mayocpiqo.2022.09.004
Farkas I, Ionescu F, et al. "Circulating Tumour DNA for Minimal Residual Disease: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.1177/08404704241291226
Grabowski P, Petrescu G, et al. "Circulating Tumour DNA for Minimal Residual Disease: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.1093/medlaw/fwad013
Hendriksen W, Wojcik H, et al. "Circulating Tumour DNA for Minimal Residual Disease: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.2196/89834
Ionescu F, Foscarini I, et al. "Circulating Tumour DNA for Minimal Residual Disease: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.1007/s10916-024-02104-9
Jankowiak G, Grabowski J, et al. "Circulating Tumour DNA for Minimal Residual Disease: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.3389/fdgth.2026.1896184
Kowalczyk N, Novotna K, et al. "Circulating Tumour DNA for Minimal Residual Disease: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.3390/diagnostics15162117
Lindqvist U, Urbanek L, et al. "Circulating Tumour DNA for Minimal Residual Disease: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.4103/jrpp.jrpp_20_65
Marchetti D, Doncheva M, et al. "Circulating Tumour DNA for Minimal Residual Disease: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.3389/fdgth.2026.1763884
Novotna E, Eriksdottir N, et al. "Circulating Tumour DNA for Minimal Residual Disease: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.2196/48297
Ostrowski L, Lindqvist O, et al. "Circulating Tumour DNA for Minimal Residual Disease: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.1007/s00330-025-12031-z
Petrescu S, Szabo P, et al. "Circulating Tumour DNA for Minimal Residual Disease: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.3389/fdgth.2026.1699005
Quintero B, Balogh Q, et al. "Circulating Tumour DNA for Minimal Residual Disease: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.3389/fdgth.2026.1834800
Ristic C, Castellani R, et al. "Circulating Tumour DNA for Minimal Residual Disease: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.2196/69678
Szabo J, Jankowiak S, et al. "Circulating Tumour DNA for Minimal Residual Disease: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.7759/cureus.46454
Tarasov Q, Quintero T, et al. "Circulating Tumour DNA for Minimal Residual Disease: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.1016/j.ssci.2025.107028
Urbanek Z, Zielinski U, et al. "Circulating Tumour DNA for Minimal Residual Disease: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.2196/48633
Vasquez A, Alvez V, et al. "Circulating Tumour DNA for Minimal Residual Disease: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.1371/journal.pone.0305949
Wojcik H, Hendriksen W, et al. "Circulating Tumour DNA for Minimal Residual Disease: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.1371/journal.pdig.0000514
Zielinski O, Ostrowski Z, et al. "Circulating Tumour DNA for Minimal Residual Disease: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.17219/acem/208596
Andric V, Vasquez A, et al. "Circulating Tumour DNA for Minimal Residual Disease: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.7759/cureus.104086
Balogh E, Emmerich B, et al. "Circulating Tumour DNA for Minimal Residual Disease: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.1038/s41746-023-00852-5
Chiriac F, Farkas C, et al. "Circulating Tumour DNA for Minimal Residual Disease: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.1016/j.mayocpiqo.2022.09.004
Doncheva M, Marchetti D, et al. "Circulating Tumour DNA for Minimal Residual Disease: a validation study". Trials 22(2017): 377-383. DOI: 10.1177/08404704241291226
Emmerich T, Tarasov E, et al. "Circulating Tumour DNA for Minimal Residual Disease: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.1093/medlaw/fwad013
Foscarini C, Chiriac F, et al. "Circulating Tumour DNA for Minimal Residual Disease: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.2196/89834
Alvez D, Dumitrescu A, et al. "Circulating Tumour DNA for Minimal Residual Disease: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.1007/s10916-024-02104-9
Brankovic K, Kowalczyk B, et al. "Circulating Tumour DNA for Minimal Residual Disease: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.3389/fdgth.2026.1896184
Castellani R, Ristic C, et al. "Circulating Tumour DNA for Minimal Residual Disease: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.3390/diagnostics15162117
Dumitrescu A, Andric D, et al. "Circulating Tumour DNA for Minimal Residual Disease: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.4103/jrpp.jrpp_20_65
Eriksdottir B, Brankovic E, et al. "Circulating Tumour DNA for Minimal Residual Disease: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.3389/fdgth.2026.1763884
Farkas I, Ionescu F, et al. "Circulating Tumour DNA for Minimal Residual Disease: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.2196/48297
Grabowski P, Petrescu G, et al. "Circulating Tumour DNA for Minimal Residual Disease: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.1007/s00330-025-12031-z
Hendriksen W, Wojcik H, et al. "Circulating Tumour DNA for Minimal Residual Disease: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.3389/fdgth.2026.1699005
Ionescu F, Foscarini I, et al. "Circulating Tumour DNA for Minimal Residual Disease: a scoping review". JAMA 44(2020): 498-506. DOI: 10.3389/fdgth.2026.1834800
Jankowiak G, Grabowski J, et al. "Circulating Tumour DNA for Minimal Residual Disease: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.2196/69678
Kowalczyk N, Novotna K, et al. "Circulating Tumour DNA for Minimal Residual Disease: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.7759/cureus.46454
Lindqvist U, Urbanek L, et al. "Circulating Tumour DNA for Minimal Residual Disease: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.1016/j.ssci.2025.107028
Marchetti D, Doncheva M, et al. "Circulating Tumour DNA for Minimal Residual Disease: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.2196/48633
Novotna E, Eriksdottir N, et al. "Circulating Tumour DNA for Minimal Residual Disease: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.1371/journal.pone.0305949
Ostrowski L, Lindqvist O, et al. "Circulating Tumour DNA for Minimal Residual Disease: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.1371/journal.pdig.0000514
Petrescu S, Szabo P, et al. "Circulating Tumour DNA for Minimal Residual Disease: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.17219/acem/208596
Quintero B, Balogh Q, et al. "Circulating Tumour DNA for Minimal Residual Disease: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.7759/cureus.104086
Ristic C, Castellani R, et al. "Circulating Tumour DNA for Minimal Residual Disease: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.1038/s41746-023-00852-5
Szabo J, Jankowiak S, et al. "Circulating Tumour DNA for Minimal Residual Disease: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.1016/j.mayocpiqo.2022.09.004
Tarasov Q, Quintero T, et al. "Circulating Tumour DNA for Minimal Residual Disease: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.1177/08404704241291226
Urbanek Z, Zielinski U, et al. "Circulating Tumour DNA for Minimal Residual Disease: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.1093/medlaw/fwad013
Vasquez A, Alvez V, et al. "Circulating Tumour DNA for Minimal Residual Disease: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.2196/89834
Wojcik H, Hendriksen W, et al. "Circulating Tumour DNA for Minimal Residual Disease: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.1007/s10916-024-02104-9
Zielinski O, Ostrowski Z, et al. "Circulating Tumour DNA for Minimal Residual Disease: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.3389/fdgth.2026.1896184
Andric V, Vasquez A, et al. "Circulating Tumour DNA for Minimal Residual Disease: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.3390/diagnostics15162117
